New Hidradenitis Suppurativa Therapies Show Promise
Experimental treatments targeting inflammatory cytokines have improved skin outcomes for patients with this chronic condition.
Updated on Oct. 3, 2026 in Diseases — General
Live Poll
Do you trust that new medical treatments will improve long-term outcomes for chronic skin conditions?
Recent clinical trials for tulisokibart, abdakibart, and lutikizumab demonstrated significant symptom relief for people living with hidradenitis suppurativa. These results, presented at the 2026 EADV Congress, provide new evidence for therapies that directly target the inflammatory pathways driving this disease.
Why it matters
Hidradenitis suppurativa is characterized by elevated neutrophil counts and cytokine expression, and these findings represent a shift toward precision therapies that may better manage the underlying inflammation of the condition.
Phase 2 trials involving 149 to 167 patients each showed that these monoclonal antibodies successfully reduced skin inflammation and clinical lesion counts. Tulisokibart and abdakibart specifically achieved positive response benchmarks by Week 16, while lutikizumab reduced key inflammatory biomarkers.
The players
EADV
The European Academy of Dermatology and Venereology is a professional society that hosts annual congresses to disseminate clinical research.
The details
Tulisokibart and abdakibart are monoclonal antibodies that function by blocking specific inflammatory cytokines involved in the disease process. Lutikizumab works by lowering neutrophil counts and inhibiting pathogenic fibroblast activity, which helps prevent the abnormal tissue remodeling that occurs in lesional skin. By directly targeting these pathways, these therapies aim to stop the localized immune response that causes hidradenitis suppurativa flare-ups.
Timeline
2026: EADV Congress took place in Vienna.
Week 4: Tulisokibart treatment responses began separating from placebo.
Week 16: Clinical response endpoints were measured for tulisokibart and abdakibart.
Health Landscape
These clinical findings follow a trend of leveraging targeted monoclonal antibodies to address inflammatory skin diseases where traditional options have often fallen short. This research marks a departure from broad immunosuppression toward precision molecular interventions for chronic dermatological conditions.
If you are managing hidradenitis suppurativa, these results highlight a developing area of medicine focused on specific inflammatory targets. Discussing the potential for emerging clinical trial opportunities with your dermatologist is a productive step for those seeking to understand new treatment options.
The takeaway
These study results illustrate the potential for targeted cytokine inhibition to improve outcomes in chronic inflammatory skin diseases. Keep track of updates regarding Phase 3 trial enrollments as these investigational therapies move closer to clinical practice.
Further reading
Learn more about the latest innovations in Diseases — General.
Live Poll
Do you trust that new medical treatments will improve long-term outcomes for chronic skin conditions?
